目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed...目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed数据库进行检索,检索时间为自建库至2022年12月。纳入标准:(1)HER-2低表达乳腺癌的生物学和临床特征;(2)ADCs药物的临床前试验和临床试验。排除标准:(1)个案报道;(2)重复的临床试验。最终纳入50篇文献。结果随着ADCs药物临床数据的不断公布,HER-2低表达乳腺癌的概念逐渐被重视。HER-2低表达乳腺癌有望成为一个全新的治疗亚型。以T-Dxd为代表的ADCs药物,包括Trastuzumab-emtansine、Trastuzumab-deruxtecan、Trastuzumab-Duocarmazine、ARX-788、XMT-1522、MEDI4276、A166和MRG002已经在HER-2低表达乳腺癌人群中展示出较好的疗效,相信新型ADCs在不久的未来能够成为HER-2低表达乳腺癌人群的治疗新选择。结论以T-Dxd为代表的新型ADCs的不断问世将成为HER-2低表达乳腺癌人群的治疗新选择,并改善该人群的预后。展开更多
The DESTINY-Breast04(DB-04)trial is a phaseⅢclinical trial that examined the efficacy of trastuzumab deruxtecan(T-DXd),an anti-HER2-antibody drug,in patients with low HER2 expression(HER2-low)advanced breast cancer.T...The DESTINY-Breast04(DB-04)trial is a phaseⅢclinical trial that examined the efficacy of trastuzumab deruxtecan(T-DXd),an anti-HER2-antibody drug,in patients with low HER2 expression(HER2-low)advanced breast cancer.The study enrolled patients with HER2-low,unresectable,and/or recurrent metastatic breast cancer(mBC)who were resistant to previous endocrine therapy and had received one or two previous lines of chemotherapy.Among the 557 enrolled patients,494(88.7%)patients had hormone receptor-positive(HR+)mBC and 63(11.3%)patients had hormone receptor-negative(HR−)mBC.展开更多
文摘目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed数据库进行检索,检索时间为自建库至2022年12月。纳入标准:(1)HER-2低表达乳腺癌的生物学和临床特征;(2)ADCs药物的临床前试验和临床试验。排除标准:(1)个案报道;(2)重复的临床试验。最终纳入50篇文献。结果随着ADCs药物临床数据的不断公布,HER-2低表达乳腺癌的概念逐渐被重视。HER-2低表达乳腺癌有望成为一个全新的治疗亚型。以T-Dxd为代表的ADCs药物,包括Trastuzumab-emtansine、Trastuzumab-deruxtecan、Trastuzumab-Duocarmazine、ARX-788、XMT-1522、MEDI4276、A166和MRG002已经在HER-2低表达乳腺癌人群中展示出较好的疗效,相信新型ADCs在不久的未来能够成为HER-2低表达乳腺癌人群的治疗新选择。结论以T-Dxd为代表的新型ADCs的不断问世将成为HER-2低表达乳腺癌人群的治疗新选择,并改善该人群的预后。
文摘The DESTINY-Breast04(DB-04)trial is a phaseⅢclinical trial that examined the efficacy of trastuzumab deruxtecan(T-DXd),an anti-HER2-antibody drug,in patients with low HER2 expression(HER2-low)advanced breast cancer.The study enrolled patients with HER2-low,unresectable,and/or recurrent metastatic breast cancer(mBC)who were resistant to previous endocrine therapy and had received one or two previous lines of chemotherapy.Among the 557 enrolled patients,494(88.7%)patients had hormone receptor-positive(HR+)mBC and 63(11.3%)patients had hormone receptor-negative(HR−)mBC.